Free Trial

Vivos Therapeutics Q1 2023 Earnings Report

Vivos Therapeutics logo
$2.61 +0.04 (+1.56%)
As of 12:11 PM Eastern

Vivos Therapeutics EPS Results

Actual EPS
-$5.00
Consensus EPS
-$4.25
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A

Vivos Therapeutics Revenue Results

Actual Revenue
$3.86 million
Expected Revenue
$3.71 million
Beat/Miss
Beat by +$150.00 thousand
YoY Revenue Growth
N/A

Vivos Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Vivos Therapeutics Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Vivos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email.

About Vivos Therapeutics

Vivos Therapeutics (NASDAQ:VVOS), a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

View Vivos Therapeutics Profile

More Earnings Resources from MarketBeat